Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT)
conducted a revision of the 2009 guidelines by updating the evidence and …

Background Major depressive disorder (MDD) is a global public health concern. In
particular, treatment-resistant depression (TRD) represents a key unmet need in the …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

We present a comprehensive overview of the neurobiology of unipolar major depression
and antidepressant drug action, integrating data from affective neuroscience, neuro-and …

Objectives. This 2013 update of the practice guidelines for the biological treatment of
unipolar depressive disorders was developed by an international Task Force of the World …

Importance Currently, fewer than 40% of patients treated for major depressive disorder
achieve remission with initial treatment. Identification of a biological marker that might …

Although monoaminergic antidepressants revolutionized the treatment of Major Depressive
Disorder (MDD) over a half-century ago, approximately one third of depressed patients …

Up to one third of patients adequately treated for Major Depressive Disorder (MDD) do not
respond to multiple interventions. Many studies investigated predictors in MDD outcome, but …

Background Antidepressants are a first‐line treatment for adults with moderate to severe
major depression. However, many people prescribed antidepressants for depression don't …

Background Although antidepressants are often a first‐line treatment for adults with
moderate to severe depression, many people do not respond adequately to medication, and …